Investment Thesis
Dianthus Therapeutics is a pre-revenue stage biopharmaceutical company burning $29M annually with minimal $2M revenue and massive operating losses (-2285% margin). While the $628M cash position and negligible debt provide 20+ years of runway, the complete absence of profitable operations and commercial traction presents substantial fundamental weakness for a company at this stage of development.
Strengths
- Exceptional liquidity with $628M cash against $46M liabilities (13.8x ratio)
- Zero long-term debt and minimal financial obligations reduce capital structure risk
- Strong balance sheet ($1.2B assets) with 20+ year cash runway at current burn rate
Risks
- Extreme unprofitability: -$46.5M operating loss and -$40.8M net loss on $2M revenue
- Negative free cash flow of -$29.1M annually indicating pure R&D spend with no commercial validation
- Early-stage biotech with minimal revenue suggests pipeline execution risk and regulatory approval uncertainty
Key Metrics to Watch
- Monthly cash burn rate and cash runway extension
- Revenue growth trajectory and product approval milestones
- Operating cash flow improvement toward breakeven
- Clinical pipeline advancement and trial success rates
Financial Metrics
Revenue
2.0M
Net Income
-40.8M
EPS (Diluted)
$-0.85
Free Cash Flow
-29.1M
Total Assets
1.2B
Cash
627.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,285.5%
Net Margin
-2,005.6%
ROE
-3.4%
ROA
-3.3%
FCF Margin
-1,429.3%
Balance Sheet & Liquidity
Current Ratio
29.25x
Quick Ratio
29.25x
Debt/Equity
0.00x
Debt/Assets
3.7%
Interest Coverage
-285.48x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T08:16:10.733979 |
Data as of: 2026-03-31 |
Powered by Claude AI